PL2520575T3 - Związek 1,3,4-oksadiazolo-2-karboksyamidowy - Google Patents
Związek 1,3,4-oksadiazolo-2-karboksyamidowyInfo
- Publication number
- PL2520575T3 PL2520575T3 PL10841060T PL10841060T PL2520575T3 PL 2520575 T3 PL2520575 T3 PL 2520575T3 PL 10841060 T PL10841060 T PL 10841060T PL 10841060 T PL10841060 T PL 10841060T PL 2520575 T3 PL2520575 T3 PL 2520575T3
- Authority
- PL
- Poland
- Prior art keywords
- oxadiazole
- carboxamide compound
- carboxamide
- compound
- Prior art date
Links
- -1 1,3,4-oxadiazole-2-carboxamide compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009297960 | 2009-12-28 | ||
| EP10841060.6A EP2520575B1 (en) | 2009-12-28 | 2010-12-28 | 1,3,4-oxadiazole-2-carboxamide compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2520575T3 true PL2520575T3 (pl) | 2017-05-31 |
Family
ID=44226607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10841060T PL2520575T3 (pl) | 2009-12-28 | 2010-12-28 | Związek 1,3,4-oksadiazolo-2-karboksyamidowy |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8796320B2 (pl) |
| EP (1) | EP2520575B1 (pl) |
| JP (1) | JP5794922B2 (pl) |
| KR (1) | KR101778320B1 (pl) |
| CN (1) | CN102725287B (pl) |
| AU (1) | AU2010339271B2 (pl) |
| CA (1) | CA2785679C (pl) |
| EA (1) | EA022458B1 (pl) |
| ES (1) | ES2610248T3 (pl) |
| NZ (1) | NZ600837A (pl) |
| PL (1) | PL2520575T3 (pl) |
| TW (1) | TWI523851B (pl) |
| WO (1) | WO2011081205A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101637246B1 (ko) | 2009-12-04 | 2016-07-07 | 선오비온 파마슈티컬스 인코포레이티드 | 다환형 화합물 및 이의 사용 방법 |
| KR101913619B1 (ko) * | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| EP3373935B1 (en) * | 2015-11-12 | 2021-09-01 | Merck Sharp & Dohme Corp. | Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use |
| SG11201900687VA (en) | 2016-07-29 | 2019-02-27 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| CN116283877A (zh) | 2016-07-29 | 2023-06-23 | 赛诺维信制药公司 | 化合物、组合物及其用途 |
| US10973829B2 (en) | 2016-09-19 | 2021-04-13 | Novartis Ag | Therapeutic uses of a C-RAF inhibitor |
| WO2018151861A1 (en) | 2017-02-16 | 2018-08-23 | Sunovion Pharamaceuticials Inc. | Methods of treating schizophrenia |
| WO2018187479A1 (en) | 2017-04-04 | 2018-10-11 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
| IL311471A (en) | 2017-05-02 | 2024-05-01 | Novartis Ag | Combination therapy |
| JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
| CN109535146B (zh) * | 2017-09-21 | 2020-09-22 | 中国医学科学院医药生物技术研究所 | 抗结核化合物及其制备方法和用途 |
| EP3752508A1 (en) | 2018-02-16 | 2020-12-23 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
| TWI826531B (zh) | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| EP3897630B1 (en) | 2018-12-21 | 2024-01-10 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
| US11447482B1 (en) | 2019-02-14 | 2022-09-20 | KUDA Therapeutics, Inc. | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis |
| CN113784755B (zh) | 2019-03-14 | 2024-05-10 | 赛诺维信制药公司 | 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 |
| JP2022527114A (ja) | 2019-04-05 | 2022-05-30 | カイメラ セラピューティクス， インコーポレイテッド | 分解剤およびそれらの使用 |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| AU2020321956A1 (en) | 2019-07-31 | 2022-03-10 | Boehringer Ingelheim International Gmbh | Heterobicyclic amides as inhibitors of CD38 |
| JP7689076B2 (ja) * | 2019-09-09 | 2025-06-05 | Ｅａファーマ株式会社 | １，５－ベンゾチアゼピン化合物を製造するための方法 |
| EP4135690B1 (en) | 2020-04-14 | 2026-03-25 | Sumitomo Pharma America, Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating, preventing and/or managing a neurological and/or psychiatric disorder |
| WO2022216930A1 (en) * | 2021-04-08 | 2022-10-13 | Virginia Commonwealth University | Novel mda-9 antagonist with anti-metastatic potential |
| JP2025542036A (ja) * | 2022-12-31 | 2025-12-24 | ナンキン イムノファージ バイオメディカル カンパニー リミテッド | マクロファージ遊走阻害因子阻害剤としての化合物及びその使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7429593B2 (en) * | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| AU2003299472A1 (en) | 2002-05-06 | 2004-07-22 | Vertex Pharmaceuticals Incorporated | Thiadiazoles or oxadiazoles and their use as inhibitors of JAK kinase |
| US7683097B2 (en) * | 2004-05-27 | 2010-03-23 | Propharmacon Inc. | Topoisomerase inhibitors |
| JP2008516989A (ja) | 2004-10-19 | 2008-05-22 | コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー | 組成物及び抗腫瘍剤としてのその使用 |
| UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| DK2200431T3 (en) * | 2007-09-10 | 2016-08-15 | Boston Biomedical Inc | UNKNOWN COMPOSITIONS AND PROCEDURES FOR CANCER TREATMENT |
| JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| WO2009149192A1 (en) | 2008-06-04 | 2009-12-10 | Baylor College Of Medicine | Stat3 inhibitors |
| WO2010004761A1 (ja) * | 2008-07-10 | 2010-01-14 | 一般社団法人ファルマＩｐ | キノリンカルボキサミド誘導体を有効成分とするｓｔａｔ３阻害剤 |
-
2010
- 2010-12-28 EP EP10841060.6A patent/EP2520575B1/en active Active
- 2010-12-28 EA EA201290397A patent/EA022458B1/ru not_active IP Right Cessation
- 2010-12-28 PL PL10841060T patent/PL2520575T3/pl unknown
- 2010-12-28 CN CN201080059883.3A patent/CN102725287B/zh not_active Expired - Fee Related
- 2010-12-28 JP JP2011547732A patent/JP5794922B2/ja not_active Expired - Fee Related
- 2010-12-28 CA CA2785679A patent/CA2785679C/en active Active
- 2010-12-28 US US13/519,707 patent/US8796320B2/en active Active
- 2010-12-28 WO PCT/JP2010/073787 patent/WO2011081205A1/ja not_active Ceased
- 2010-12-28 ES ES10841060.6T patent/ES2610248T3/es active Active
- 2010-12-28 NZ NZ600837A patent/NZ600837A/en not_active IP Right Cessation
- 2010-12-28 KR KR1020127016740A patent/KR101778320B1/ko not_active Expired - Fee Related
- 2010-12-28 AU AU2010339271A patent/AU2010339271B2/en not_active Ceased
- 2010-12-28 TW TW099146436A patent/TWI523851B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US8796320B2 (en) | 2014-08-05 |
| KR20120109530A (ko) | 2012-10-08 |
| CN102725287B (zh) | 2015-07-01 |
| AU2010339271B2 (en) | 2015-09-03 |
| EP2520575B1 (en) | 2016-11-30 |
| EP2520575A4 (en) | 2013-12-11 |
| KR101778320B1 (ko) | 2017-09-13 |
| ES2610248T3 (es) | 2017-04-26 |
| JPWO2011081205A1 (ja) | 2013-05-13 |
| TW201127832A (en) | 2011-08-16 |
| EP2520575A1 (en) | 2012-11-07 |
| EA022458B1 (ru) | 2016-01-29 |
| WO2011081205A1 (ja) | 2011-07-07 |
| CA2785679C (en) | 2017-12-12 |
| CA2785679A1 (en) | 2011-07-07 |
| US20120302524A1 (en) | 2012-11-29 |
| NZ600837A (en) | 2014-01-31 |
| AU2010339271A1 (en) | 2012-07-19 |
| CN102725287A (zh) | 2012-10-10 |
| TWI523851B (zh) | 2016-03-01 |
| JP5794922B2 (ja) | 2015-10-14 |
| EA201290397A1 (ru) | 2013-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2520575T3 (pl) | Związek 1,3,4-oksadiazolo-2-karboksyamidowy | |
| EP2361902A4 (en) | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG | |
| ZA201108962B (en) | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 | |
| SI2384326T1 (sl) | Pirolo(2,3-d)pirimidinske spojine | |
| GB0913345D0 (en) | New combination 802 | |
| SI2356123T1 (sl) | Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni | |
| GB0804989D0 (en) | Compound | |
| SI2513119T1 (sl) | 3,4,4a,10b-tetrahidro-1H-tiopirano-(4,3-c)izokinolinski derivati | |
| GB201203224D0 (en) | Substitute 1,2-azaborne heterocycles | |
| GB0900404D0 (en) | New compounds 4 | |
| GB0803494D0 (en) | Compound | |
| IL214110A0 (en) | 2,3-diaryl-or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds | |
| IL207035A0 (en) | Benzylpiperizine compound | |
| SI2266990T1 (sl) | Spojina 3-fenilpirazolo(5,1-b)tiazola | |
| GB0912946D0 (en) | New compounds 5 | |
| AP2011005932A0 (en) | Pyrazinoisoquinoline Compounds. | |
| IL213762A0 (en) | 1,1,1-trifluoro-2-hydroxypropyl compounds | |
| GB201208654D0 (en) | Moisturing composition | |
| ZA201202652B (en) | Pesticidal compositions comprising 4,5-dihydroxyindan-1-one | |
| GB0823316D0 (en) | Compound | |
| GB0900385D0 (en) | Lasha2A.1 | |
| GB0918322D0 (en) | Compounds 814 | |
| GB0913344D0 (en) | Compounds 762 | |
| GB0912947D0 (en) | New compounds 6 | |
| GB0900400D0 (en) | New compounds 3 |